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1  | CLINIC AL TRIAL S OF T YPE I 
INTERFERONS ( IFN-I)  AGAINST SARS-
COV-2
SARS-CoV-2 is a novel single-stranded RNA (ssRNA) coronavirus 
that emerged in China in December of 2019 that has infected more 
than 6 million people worldwide and is responsible for over 350, 000 
deaths as of May of 2020. In the absence of a vaccine or effective 
treatment, numerous novel or repurposed antiviral drugs and ther-
apies are being considered,1,2 including type 1 interferons (IFN-I).2 
IFN-I is a family of cytokines with potent antiviral properties that 
mediate the early innate immune response to viral infections.3 IFN-I 
is comprised of α and β subtypes (IFNα, IFNβ),3 which are secreted by 
a number of cell types, including pulmonary epithelial cells, macro-
phages, but most notably plasmacytoid dendritic cells (pDC).4 IFN-I 
mediates cellular immune actions through activation of membrane 
interferon-α/β receptor (IFNAR) and the downstream regulation and 
expression of IFN-stimulated genes (ISGs), which act to inhibit of 
viral replication and stimulate adaptive immune responses.4
There are currently a number of clinical trials being conducted 
to examine the combinations of IFNα with antiviral drugs lopinavir/
ritonavir (ChiCTR2000029387), favipiravir (ChiCTR2000029600), 
and lopinavir/ritonavir + glucocorticoids (ChiCTR2000029386), or 
IFNβ in combination with lopinavir/ritonavir and ribavirin for treat-
ment of SARS-CoV-2 (NCT04276688).5 Use of IFNα treatment is 
part of the latest edition of the standards of clinical care and treat-
ment of patients with SARS-CoV-2 published by the National Health 
Commission (NHC) of the People's Republic of China. The protocol 
is 5 million U of IFN-α by vapour inhalation in combination with rib-
avirin twice per day.1
2  | CORONAVIRUS E VA SION OF IFN-I 
ANTIVIR AL RESPONSES
To date, no studies that have examined if IFN-I can inhibit SARS-
CoV-2 in cells or animal models; however, there is a large body 
data that IFN-I is effective in inhibiting two closely related coro-
naviruses, SARS-CoV and MERS-CoV in vitro, either alone or in 
combination with antiviral drugs.6 Results of the clinical efficacy 
of IFN-I against SARS-CoV and MERS-CoV in human studies, 
however, are mixed and overall IFN-I treatments typically fail to 
significantly mitigate these coronavirus infections in humans.6 
It is unclear why there is a lack of consistent clinical efficacy of 
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Abstract
The 2020 global outbreak of the novel coronavirus (SARS-CoV-2 or COVID-19) is a 
serious threat to international health, and thus, there is an urgent need for discovery 
of novel therapies or use of repurposed drugs that can make a significant impact on 
slowing the spread of the virus. Type 1 interferons (IFN-I) are a family cytokines of 
the early innate immune response to viruses that are being tested against SARS-
CoV-2. However, coronaviruses similar to SARS-CoV-2 can suppress host IFN-I an-
tiviral responses. Retinoids are a family molecules related to vitamin A that possess 
robust immune-modulating properties, including the ability to increase and potenti-
ate the actions of IFN-I. Therefore, adjuvants such as retinoids, capable of increasing 
IFN-I-mediated antiviral responses, should be tested in combinations of IFN-I and 
antiviral drugs in pre-clinical studies of SARS-CoV-2.
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2  |     LETTER TO EDITOR
IFN-I in human trials given the known antiviral properties of IFN-I. 
Evidence suggests that the timing of IFN-I administration and the 
presence and severity of comorbidities in patients infected with 
coronaviruses are some of the determinants of clinical response 
to IFN-I treatments.7,8
There is also a convincing body of evidence demonstrating that 
SARS-CoV and MERS-CoV, like many viruses, can disrupt the IFN-I 
signalling in host cells.9-12 For example, SARS-CoV can suppress host 
IFN-I responses by inhibiting interferon regulatory factor 3 (IRF-3), 
a key transcription factor required for IFN-I promoter activation, 
and retinoic acid-induced gene I (RIG-I).10,11 RIG-I is a pattern rec-
ognition receptor responsible for sensing RNA viruses and plays a 
key role in inducing IFN-I and the early innate antiviral immune re-
sponses.13 Activated RIG-I signals through IRF-3 and NF-κB, which 
increase the mRNA expression of numerous antiviral genes includ-
ing IFN-I and type III interferons.13 MERS-CoV can also antagonize 
RIG-I13 and IFN-I antiviral responses through ORF4b-encoded 
accessory proteins.12 It is therefore reasonable to predict that, as 
part of its immune-evasive programme, SARS-CoV-2 would act to 
disrupt IFN-I-mediated antiviral responses in a similar fashion. These 
data suggest that adjuvants capable of stimulating and enhancing 
the antiviral effects of IFN-I should be given serious consideration 
when developing anti-SARS-CoV-2 pharmacological and treatment 
protocols.
3  | RETINOIDS A S IMMUNOMODUL ATORS 
AND POTENTIAL ADJUVANTS WITH IFN-I 
PROTOCOL S FOR SARS- COV-2
Retinoids are a family of molecules that possess qualitative activity 
relative to all-trans retinol (vitamin A) that includes retinyl-esters, all-
trans retinal and all-trans-retinoic acid (RA).14 RA is the biologically 
active retinoid metabolite that, acting through its cognate receptors 
RA receptors (RAR α, β and γ), regulates the expression of genes in-
volved numerous biological pathways including both adaptive and 
innate immune responses [reviewed in 15]. Retinoids act as effec-
tors of the T-cell-mediated adaptive immunity and innate immune 
responses through stimulation of NK cells, antigen-presenting den-
dritic cells (DCs) and innate lymphoid cells (ILCs).15,16 The rationale 
for testing the combination of retinoids and IFN-I is strong and based 
on a large body of pre-clinical and clinical data showing that retinoids 
stimulate secretion and potentiate the effects of IFN-I.17,18 Retinoids 
can directly stimulate the mRNA expression of ISGs, including RIG-I, 
and IFN regulatory factor 1 (IRF-1).16,17,19-21 The IFN-I-potentiating 
effects of retinoids have been documented in cell and animal models 
of cancer, in human cancer clinical trials17,19 and in treatment of mul-
tiple sclerosis (MS).22 Qu et al22 reported that RA-treated peripheral 
blood mononuclear cells from patients with MS increased IFN-β re-
sponse and restored CD8+ T-suppressor cell functions. Similarly, in 
phase 1 clinical trials in patients with MS, it was reported that treat-
ments with the synthetic retinoid Etretinate enhanced the effect of 
IFN-β on T-cell function and restoration of T suppressors.23
A key mechanism through which retinoids enhance IFN-I is with 
activation of RIG-I. As the name indicates, RIG-I is stimulated by 
RA, and numerous lines of evidence support that IFN-I enhancing 
and antiviral effect of retinoids occurs through direct stimulation 
of RIG-I mRNA and functions.24-26 Soye et al24 demonstrated that 
RA inhibition of measles virus (MeV) replication in U9370 and Huh-
7-infected cells occurs through IFN-I-mediated pathways driven by 
RA:RARα promoter activation of the RIG-I gene and its downstream 
effectors. Similarly, Chen et al reported that the antiviral effects of 
RA against enterovirus 71 are mediated through IFN-α and RIG-I.25 
Natural and synthetic retinoids also have direct inhibitory effects 
on replication of a number of viruses, including hepatitis B virus 
(HBV), cytomegalovirus, influenza, MeV, and norovirus.27-30 There 
is also evidence that activation of retinoid signalling can potently 
inhibit coronaviruses.31 Through a library screen, Yuan et al demon-
strated that Am580, a specific agonist for RARα, is a potent inhibitor 
of SARS-CoV and MERS-CoV viruses through disruption of SREBP-
mediated lipogenic pathways.31
Given that the coronaviruses SARS-CoV and MERS-CoV can in-
hibit IFN-I mediated antiviral responses and possibly hinder treat-
ments,9-12 the data supporting that retinoids can potentiate host 
IFN-I signalling, and their well-documented safety profiles after 
almost 60 years of clinical use14 warrant the pre-clinical testing of 
combinations of IFN-I and retinoids in cell and animal models of 
SARS-CoV-2.
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